To Evaluate a Phase I/II Clinical Study of XNW5004 Tablets in Patients With Relapsed/Refractory Advanced Tumors

NCT06558513 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Tumor
Lymphoma

Interventions

DRUG: XNW5004 tablets

Sponsor

Evopoint Biosciences Inc.